Hologic Inc. reported GAAP net income of $86.5 million, or 30 cents per share, for the fiscal first quarter of 2017, versus $84.9 million, or 29 cents per share, in the year-ago period.
Non-GAAP net income was $148.1 million, or 52 cents per share, compared with $135.1 million, or 46 cents per share, for the fiscal first quarter of 2016.
The S&P Capital IQ consensus normalized EPS estimate for the fiscal first quarter of 2017 was 51 cents.
Revenues for the quarter totaled $734.4 million, versus $695.2 million in the comparable year-ago period.
The U.S. sales of $573.6 million rose 5.2% and international sales of $160.8 million increased 7.2% year over year. The rise in international sales was led by strong growth in blood screening, molecular diagnostics and GYN Surgical. Excluding blood screening, international sales rose 2.7%.
For the second quarter of fiscal 2017, revenues are expected to be $675 million to $685 million. GAAP EPS for the quarter is expected to be $1.85 to $1.86, with non-GAAP EPS expected between 45 cents and 46 cents. The S&P Capital IQ consensus normalized EPS estimate for the fiscal second quarter is 50 cents.
Hologic expects total revenues of $2.79 billion to $2.83 billion for fiscal 2017. Previously, they were expected to be $2.94 billion to $2.98 billion. Hologic expects GAAP EPS of $2.73 to $2.77 for the year, compared with previous EPS expectations of $1.23 to $1.27.
Non-GAAP EPS for fiscal 2017 is expected to be between $1.90 and $1.94, versus prior expectations of $2.12 to $2.16.
The S&P Capital IQ consensus normalized EPS estimate for the fiscal 2017 is $2.07.